Rhythm Pharmaceuticals, Inc.
RYTM
$50.97
$0.731.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 130.13M | 112.53M | 101.78M | 91.93M | 77.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 130.13M | 112.53M | 101.78M | 91.93M | 77.43M |
| Cost of Revenue | 13.37M | 12.82M | 11.40M | 10.69M | 9.30M |
| Gross Profit | 116.76M | 99.72M | 90.38M | 81.24M | 68.13M |
| SG&A Expenses | 144.30M | 138.55M | 133.65M | 127.28M | 117.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 395.63M | 378.05M | 367.37M | 363.64M | 261.78M |
| Operating Income | -265.51M | -265.52M | -265.58M | -271.71M | -184.35M |
| Income Before Tax | -260.22M | -258.28M | -258.09M | -273.01M | -184.11M |
| Income Tax Expenses | 345.00K | 631.00K | 1.34M | 864.00K | 564.00K |
| Earnings from Continuing Operations | -260.57 | -258.91 | -259.43 | -273.87 | -184.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -260.57M | -258.91M | -259.43M | -273.87M | -184.68M |
| EBIT | -265.51M | -265.52M | -265.58M | -271.71M | -184.35M |
| EBITDA | -263.94M | -263.92M | -263.93M | -270.00M | -182.60M |
| EPS Basic | -4.36 | -4.34 | -4.37 | -4.64 | -3.21 |
| Normalized Basic EPS | -2.68 | -2.68 | -2.70 | -2.89 | -2.00 |
| EPS Diluted | -4.36 | -4.34 | -4.37 | -4.64 | -3.21 |
| Normalized Diluted EPS | -2.68 | -2.68 | -2.70 | -2.89 | -2.00 |
| Average Basic Shares Outstanding | 243.97M | 241.59M | 238.24M | 234.10M | 230.66M |
| Average Diluted Shares Outstanding | 243.97M | 241.59M | 238.24M | 234.10M | 230.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
